StockData
Lipocine Inc. logo

Lipocine Inc. (LPCN) stock

LPCNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3039% below fair value
$1.60−0.06 (-3.61%)

Close on Nov 17, 2026Market cap $13.19MP/E –Yield –

Lipocine operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Lipocine's operating cash flow for the twelve months ending Jun 30, 2026 was -$11.19M. For fiscal 2025 it was -$9.76M. The highest annual figure on record is -$7.30K in fiscal 2011.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$9.76M–
FY2024Dec 31, 2024-$1.22M–
FY2023Dec 31, 2023-$11.87M–
FY2022Dec 31, 2022-$11.97M–
FY2021Dec 31, 2021-$4.41M–
FY2020Dec 31, 2020-$15.30M–
FY2019Dec 31, 2019-$11.67M–
FY2018Dec 31, 2018-$12.08M–
FY2017Dec 31, 2017-$16.70M–
FY2016Dec 31, 2016-$18.28M–
FY2015Dec 31, 2015-$15.36M–
FY2014Dec 31, 2014-$17.30M–
FY2013Dec 31, 2013-$8.59M–
FY2012Dec 31, 2012-$3.18M–
FY2011Dec 31, 2011-$7.30K–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.03M–
Q1 FY2026Mar 31, 2026-$2.26M–
Q4 FY2025Dec 31, 2025-$2.92M-271.5%
Q3 FY2025Sep 30, 2025-$2.99M–
Q2 FY2025Jun 30, 2025-$1.89M–
Q1 FY2025Mar 31, 2025-$1.97M-181.8%
Q4 FY2024Dec 31, 2024$1.70M–
Q3 FY2024Sep 30, 2024-$2.83M–
Q2 FY2024Jun 30, 2024-$2.50M–
Q1 FY2024Mar 31, 2024$2.41M–
Q4 FY2023Dec 31, 2023-$2.02M–
Q3 FY2023Sep 30, 2023-$2.61M–
Q2 FY2023Jun 30, 2023-$3.31M–
Q1 FY2023Mar 31, 2023-$3.93M–
Q4 FY2022Dec 31, 2022-$1.84M-120.4%
Q3 FY2022Sep 30, 2022-$3.20M–
Q2 FY2022Jun 30, 2022-$3.05M–
Q1 FY2022Mar 31, 2022-$3.89M–
Q4 FY2021Dec 31, 2021$8.99M–
Q3 FY2021Sep 30, 2021-$6.98M–
Q2 FY2021Jun 30, 2021-$2.36M–
Q1 FY2021Mar 31, 2021-$4.06M–
Q4 FY2020Dec 31, 2020-$3.68M–
Q3 FY2020Sep 30, 2020-$4.16M–
Q2 FY2020Jun 30, 2020-$4.08M–
Q1 FY2020Mar 31, 2020-$3.38M–
Q4 FY2019Dec 31, 2019-$3.31M–
Q3 FY2019Sep 30, 2019-$2.80M–
Q2 FY2019Jun 30, 2019-$2.56M–
Q1 FY2019Mar 31, 2019-$3.00M–
Q4 FY2018Dec 31, 2018-$2.23M–
Q3 FY2018Sep 30, 2018-$3.36M–
Q2 FY2018Jun 30, 2018-$2.74M–
Q1 FY2018Mar 31, 2018-$3.75M–
Q4 FY2017Dec 31, 2017-$4.30M–
Q3 FY2017Sep 30, 2017-$4.57M–
Q2 FY2017Jun 30, 2017-$4.70M–
Q1 FY2017Mar 31, 2017-$3.14M–
Q4 FY2016Dec 31, 2016-$2.55M–
Q3 FY2016Sep 30, 2016-$4.05M–

More Lipocine figures

See a number that looks wrong?